Literature DB >> 15745775

Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.

Renée Solomon1, Eric D Donnenfeld, Henry D Perry, Robert W Snyder, Chad Nedrud, Jonathan Stein, Adam Bloom.   

Abstract

PURPOSE: To investigate the aqueous penetration of 3 commercially available ophthalmic fluoroquinolones.
DESIGN: Prospective, double-masked, clinical study. PARTICIPANTS: Fifty-two eyes of 52 patients. INTERVENTION: Fifty-two patients undergoing cataract surgery were given preoperative topical gatifloxacin 0.3% (Zymar), moxifloxacin 0.5% (Vigamox), or ciprofloxacin 0.3% (Ciloxan). The patients were instructed to use their antibiotic drops 4 times a day for 3 days before surgery. On the day of surgery, patients were given their assigned antibiotic every 15 minutes for 3 doses, 1 hour before their procedure. At the time of surgery, 0.1 ml of aqueous fluid was aspirated from the anterior chamber with an air cannula needle attached to a tuberculin syringe. The aspirate was immediately stored at -70 degrees C. MAIN OUTCOME MEASURE: Fluoroquinolone concentrations were determined by reverse-phase high-pressure liquid chromatography assay technique with ultraviolet detection at a wavelength of 275 nm.
RESULTS: Mean aqueous concentration of gatifloxacin in 16 eyes was 0.63 microg/ml (standard deviation [SD], 0.30), moxifloxacin in 14 eyes was 1.31 microg/ml (SD, 0.46), and the mean concentration of ciprofloxacin in 22 eyes was 0.15 microg/ml (SD, 0.11).
CONCLUSIONS: Both moxifloxacin (P<0.001) and gatifloxacin (P<0.005) penetrated the aqueous humor at significantly higher levels than ciprofloxacin. Moxifloxacin penetrated into the aqueous humor at significantly higher levels than gatifloxacin (P<0.05). The anterior chamber levels of moxifloxacin and gatifloxacin may be due to the difference in antibiotic concentration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15745775     DOI: 10.1016/j.ophtha.2004.09.029

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  23 in total

1.  Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.

Authors:  Prajna Lalitha; Muthiah Srinivasan; P Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Vicky Cevallos; Catherine E Oldenburg; Kathryn J Ray; Christine M Toutain-Kidd; David V Glidden; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2012-03-23       Impact factor: 9.079

Review 2.  [Therapy and prognosis of bacterial keratitis].

Authors:  W Behrens-Baumann; U Pleyer
Journal:  Ophthalmologe       Date:  2007-01       Impact factor: 1.059

3.  Ocular penetration and efficacy of levofloxacin using different drug-delivery techniques for the prevention of endophthalmitis in rabbit eyes with posterior capsule rupture.

Authors:  Takahiro Uda; Takashi Suzuki; Arisa Mitani; Yoshitaka Tasaka; Shiro Kawasaki; Tsuyoshi Mito; Yuichi Ohashi
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-11       Impact factor: 2.671

Review 4.  Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

5.  Clinically Compatible Fluorescence Microscopy Based on Moxifloxacin Antibiotic.

Authors:  Seunghoon Lee; Ki Hean Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model.

Authors:  Regis P Kowalski; Eric G Romanowski; Francis S Mah; Hiroshi Sasaki; Masamichi Fukuda; Y J Gordon
Journal:  Jpn J Ophthalmol       Date:  2008-07-27       Impact factor: 2.447

7.  The comparison of fluoroquinolones to nonfluoroquinolone antibacterial agents for the prevention of endophthalmitis in a rabbit model.

Authors:  Regis P Kowalski; Eric G Romanowski; Robert M Q Shanks; Francis S Mah
Journal:  J Ocul Pharmacol Ther       Date:  2012-08-27       Impact factor: 2.671

Review 8.  Gender analysis of moxifloxacin clinical trials.

Authors:  Elisa Chilet-Rosell; Ma Teresa Ruiz-Cantero; Ma Angeles Pardo
Journal:  J Womens Health (Larchmt)       Date:  2013-11-01       Impact factor: 2.681

9.  New treatments for bacterial keratitis.

Authors:  Raymond L M Wong; R A Gangwani; Lester W H Yu; Jimmy S M Lai
Journal:  J Ophthalmol       Date:  2012-09-06       Impact factor: 1.909

10.  Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract surgery.

Authors:  Sujash Halder; Kanchan Kumar Mondal; Supreeti Biswas; Tapan Kumar Mandal; Bakul Kumar Dutta; Mithilesh Haldar
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.